Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8521 to 8535 of 9024 results

  1. Durvalumab for untreated PD-L1 positive metastatic urothelial bladder cancer [ID1169]

    Discontinued Reference number: GID-TA10324

    Technology appraisal guidance
    Discontinued

  2. Durvalumab with tremelimumab for untreated PD-L1-positive urothelial bladder cancer [ID1335]

    Discontinued Reference number: GID-TA10315

    Technology appraisal guidance
    Discontinued

  3. Paclitaxel as albumin-bound nanoparticles with gemcitabine for adjuvant treatment of pancreatic cancer [ID1413]

    Discontinued Reference number: GID-TA10329

    Technology appraisal guidance
    Discontinued

  4. Nivolumab for treating platinum-resistant advanced or recurrent ovarian cancer [ID2714]

    Discontinued Reference number: GID-TA10590

    Technology appraisal guidance
    Discontinued

  5. Nivolumab in combination for treating hormone-relapsed metastatic prostate cancer after chemotherapy [ID1621]

    Discontinued Reference number: GID-TA10492

    Technology appraisal guidance
    Discontinued

  6. Nivolumab in combination for treating hormone-relapsed metastatic prostate cancer before chemotherapy [ID1619]

    Discontinued Reference number: GID-TA10490

    Technology appraisal guidance
    Discontinued

  7. Avelumab for treating non-small-cell lung cancer after platinum-based chemotherapy [ID1146]

    Discontinued Reference number: GID-TA10341

    Technology appraisal guidance
    Discontinued

  8. Nivolumab with ipilimumab for untreated PD-L1 mutation-positive non-small-cell lung cancer [ID1675]

    Discontinued Reference number: GID-TA10585

    Technology appraisal guidance
    Discontinued

  9. Atezolizumab with cobimetinib and vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma [ID1674]

    Discontinued Reference number: GID-TA10543

    Technology appraisal guidance
    Discontinued

  10. Atezolizumab with carboplatin or cisplatin and pemetrexed for untreated advanced non-squamous non-small-cell lung cancer [ID1495]

    Discontinued Reference number: GID-TA10395

    Technology appraisal guidance
    Discontinued

  11. Durvalumab for treating recurrent or metastatic squamous cell head and neck cancer [ID3752]

    Discontinued Reference number: GID-TA10617

    Technology appraisal guidance
    Discontinued

  12. Ticagrelor for preventing cardiovascular events in people with type 2 diabetes and coronary artery disease [ID1514]

    Discontinued Reference number: GID-TA10429

    Technology appraisal guidance
    Discontinued

  13. Atezolizumab with chemotherapy for neoadjuvant treatment of resectable early or locally advanced invasive triple-negative breast cancer [ID1574]

    Discontinued Reference number: GID-TA10531

    Technology appraisal guidance
    Discontinued

  14. Apalutamide with abiraterone acetate and prednisone for treating metastatic hormone-relapsed prostate cancer [ID1480]

    Discontinued Reference number: GID-TA10465

    Technology appraisal guidance
    Discontinued

  15. Tanezumab for treating moderate to severe chronic pain caused by osteoarthritis [ID1603]

    Discontinued Reference number: GID-TA10711

    Technology appraisal guidance
    Discontinued